Investor's Business Daily on MSN
Dexcom Stock, Down 15%, Is Haunted By Its 'Surprisingly Cautious' Outlook
Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.
DexCom (DXCM) is forecasting robust earnings growth of 19.2% per year and revenue growth of 11.8% per year. Both figures outpace the broader US market’s revenue growth forecast of 10.4%. Over the past ...
The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...
Stocktwits on MSN
Dexcom Stock Plunges 13% After-Hours As Q3 Margin Pressures Eclipse Record Profit — Retail Sees ‘Buy The Dip’ Setup
Investors focused on Dexcom’s lower gross margin of 61.3%, down about 170 basis points year-over-year, despite record revenue ...
DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst ...
Dexcom G6 is the first Continuous Glucose Monitoring (CGM) System to be listed by the NIHB Drug Benefit program. BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a leader in ...
Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.
Dexcom G6 was the first Continuous Glucose Monitoring (CGM) System to be officially listed by the NIHB Drug Benefit program. BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), ...
DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback